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A B S T R A C T   
The testing of anti-neutrophil cytoplasmic antibodies (ANCA) takes an important place in the diagnostic workup 
to ANCA-associated vasculitis (AAV). Nowadays, it is recommended to screen for the presence of PR3 and MPO 
specific antibodies first using immunoassay, without the need for ANCA measurement by indirect immunoflu-
orescence (IIF). A literature search was performed to assess the diagnostic test value of ANCA IIF and PR3- and 
MPO-antibody immunoassay to diagnose AAV. This meta-analysis shows that the c-ANCA testing by IIF has a 
pooled sensitivity of 75.2% and a pooled specificity of 98.4%. For PR3-antibody immunoassay, the pooled 
sensitivity depended on the immunoassay method used, and ranged from 79.8% to 86.6%, whereas the pooled 
specificity ranged from 96.8% to 98.3%. For both p-ANCA IIF and MPO-antibody immunoassay (all methods) 
sensitivity varied considerably showing pooled values of respectively 46.3% and 58.1%, whereas respective 
pooled specificity was 91.4% and 95.6%. These findings support the 2017 international consensus that primary 
anti-PR3 and anti-MPO screening by immunoassay, based on superior immunoassay sensitivity without the need 
for IIF ANCA testing, improves the diagnostic workup of AAV.   
1. Introduction 
Antineutrophil cytoplasmic antibodies (ANCA) are antibodies that 
attack cytoplasmic components of neutrophils and monocytes [1]. These 
antibodies are of major importance in detecting and classifying systemic 
vasculitides [2], such as granulomatosis with polyangiitis (GPA, previ-
ously named Wegener granulomatosis (WG)) [3], microscopic poly-
angiitis (MPA) [4] and eosinophilic granulomatosis with polyangiitis 
(eGPA, previously named Churg-Strauss Syndrome (CSS)) [5]. An in-
ternational consensus regarding the classification of ANCA-associated 
vasculitides is currently in use, namely the Chapel Hill Consensus [6]. 
GPA, MPA and eGPA are called ANCA-associated vasculitis (AAV) 
because of their similar clinical and pathological features and treatment 
options. AAV affects mostly the small and medium-sized blood vessels, 
and ANCA tests are usually positive [1,7]. These vasculitides can have 
different systemic manifestations which may damage vital organs and 
consequently lead to serious morbidity and mortality [1]. 
ANCA measurement can be used as a screening tool in clinical 
practice [8]. These measurements are commonly used as screening for 
AAV. AAV manifests itself in different ways and comes with a variety of 
symptoms. Importantly, clinicians should use ANCA screening only 
when sufficient clinical suspicion is present because it can lead to false- 
positive results [9,10]. Besides that, the prevalence of AAV is low with a 
reported number of 42/100,000 in the United States [11]. Therefore, 
some cautiousness in requesting ANCA-testing is needed. 
There are two forms of ANCA testing, namely the indirect immuno-
fluorescence assay (IIF) and the immunoassay, such as enzyme-linked 
immunosorbent assay (ELISA) [12,13]. The IIF test is performed with 
ethanol-fixed human neutrophils as substrate and hereby there are two 
main fluorescence patterns visible. ANCA can display a granular cyto-
plasmic pattern (c-ANCA) or a perinuclear pattern (p-ANCA) [9]. 
Cytoplasmic ANCA (c-ANCA) aimed towards proteinase 3 (PR3-ANCA) 
[14,15] is usually positive in patients with GPA and perinuclear ANCA 
(p-ANCA) aimed towards myeloperoxidase (MPO-ANCA) [4] often ap-
pears in patients suffering from MPA or eGPA. 
However, not all patients with systemic vasculitis are ANCA IIF 
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positive so ANCA testing with IIF may not be sensitive enough [8]. 
Furthermore, ANCAs are not specific for vasculitis because immuno-
fluorescence testing can also detect (atypical) ANCA patterns in other 
inflammatory diseases [8,16] like drug-induced vasculitis, ulcerative 
colitis, primary sclerosing cholangitis, autoimmune hepatitis, rheuma-
toid arthritis, SLE, interstitial lung disease, cystic fibrosis and infections. 
The ELISA based immunoassay makes use of purified specific antigens. 
Immunoassays detecting antibodies against PR3 and MPO usually have 
higher specificities and positive predictive values compared to IIF pat-
terns like p-ANCA and c-ANCA [17,18]. Hence, it was suggested to 
perform an immunoassay in combination with IIF [8,19]. 
There are three types of antibody immunoassay methods, based on 
their antibody detection, namely direct, capture and anchor immuno-
assay. Respectively, these tests are also called the first-generation, sec-
ond-generation and third-generation assays. In direct immunoassay, the 
carrier is directly coated with the antigen. In capture immunoassay, the 
carrier is coated with specific monoclonal antibodies that capture and 
present the antigen. Finally, in anchor immunoassay the antigen is 
bound to the carrier with a peptide linker [20]. Several antibody 
detection test systems are available that employ the above mentioned 
immunoassays, such as enzyme-linked immunosorbent assay (ELISA), 
fluorescent enzyme immunoassay (FEIA) and chemiluminescent 
immunoassay (CLIA). 
In the 1999 international consensus statement, ANCA screening by 
indirect immunofluorescence (IIF) was recommended in suspected AAV 
and in case of ANCA IIF positivity, specific detection of PR3 and MPO 
antibodies was advised [21]. Although this testing algorithm is still 
widely used, its diagnostic performance has recently been questioned. A 
more recent multicenter study showed that the diagnostic performance 
of current antigen-specific immunoassays equals or even exceeds the 
diagnostic performance of ANCA IIF to discriminate AAV from disease 
controls [22]. These findings resulted in a new international consensus. 
This 2017 international consensus on ANCA testing advised that 
immunoassay should be used as a primary screening method for diag-
nosing AAV, without the need for IIF [23]. Though data on the diag-
nostic test value of both IIF and immunoassay ANCA testing are reported 
by different research groups, a meta-analysis of the data has not yet been 
performed. This analysis could be of value in the evaluation of the new 
consensus. Therefore, we performed a systematic review and meta- 
analysis to evaluate the diagnostic value of ANCA testing using IIF and 
immunoassay (thereby comparing direct, capture and anchor immuno-
assay) in patients with AAV. 
2. Methods 
2.1. Search strategy 
For this systematic review and meta-analysis, a literature search was 
performed using the Medline (PubMed) database and finalized on the 
16th of September 2019. The search terms were: (“Anti-Neutrophil 
Cytoplasmic Antibody-Associated Vasculitis”[Mesh] AND “Diagnosis, 
Differential”[Mesh] AND “Antibodies, Antineutrophil Cyto-
plasmic”[Mesh]) OR (“Sensitivity and Specificity”[Mesh] AND “Anti-
bodies, Antineutrophil Cytoplasmic”[Mesh]) OR (“ANCA”[tiab] AND 
“Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis”[tiab] 
AND “diagnosis”[tiab]). An additional search was performed without 
Mesh terms to be able to identify the most recent publications. 
2.2. Selection criteria 
For this systematic review, eligible studies met the following inclu-
sion criteria: Investigation of the diagnostic value of cytoplasmic anti- 
neutrophil cytoplasmic antibodies (c-ANCA), perinuclear anti- 
neutrophil cytoplasmic antibodies (p-ANCA), proteinase 3 (PR3) and/ 
or myeloperoxidase (MPO) antibodies in the blood samples from pa-
tients with AAV; The sensitivity, specificity and sample size or positive 
predictive value, negative predictive value and sample size were pro-
vided; Measurements were done using indirect immunofluorescence 
and/or immunoassay. We included all forms of immunoassay, such as 
ELISA, FEIA and CLIA. Studies that only included immunofluorescence 
and not immunoassay were excluded. Letters, reviews and case reports 
were excluded. 
The study selection process was done by three researchers indepen-
dently (NG, MW and AA). First, titles and abstracts were screened based 
on relevance. The studies that did not address the research question 
were excluded. Eventually, the full-text articles were screened and a 
definite set of studies was determined. Disagreements were resolved by 
consensus. 
2.3. Data extraction and quality assessment 
Data extraction was performed by the three researchers indepen-
dently. We extracted the name of the first author, year of publication, 
type of study, sample size, number of patients and controls and diag-
nostic test values (sensitivity, specificity, positive predictive value and 
negative predictive value, or calculated these based on the reported 
patients numbers and test positivity). 
We used the Quality Assessment Tool for Diagnostic Accuracy 
Studies (QUADAS-2 tool) [24] to assess the quality of the articles, as 
advised by the Cochrane guidelines [25]. This tool evaluates each study 
on four domains, namely patient selection, index test, reference stan-
dard and timing. These domains are appraised using 14 questions, as 
described in Appendix A. A study is classified as low risk of bias when it 
has a maximum of 1 negative point in each section [24]. 
2.4. Statistical analysis 
A meta-analysis was done to estimate the sensitivity and specificity 
of c-ANCA tested by indirect immunofluorescence and for the sensitivity 
and specificity of anti-PR3 tested by immunoassay. The analysis for 
immunoassay was done separately for direct immunoassay, capture 
immunoassay and anchor immunoassay. For p-ANCA and anti-MPO a 
separate meta-analysis was performed. We used the true positives, false 
positives, false negatives and true negatives that we determined using 
the reported sensitivity, specificity, disease group and control group. 
The forest plot and summary receiver operating characteristics (SROC) 
plot were constructed using Review Manager Software 5.3 empowered 
by Cochrane Library [26]. Summary sensitivity and specificity were 
calculated with the bivariate model using the MetaDTA tool [27]. We 
derived 95% CI’s for all estimated values, including the summary 
measures. We also calculated the likelihood ratios using the sensitivity 
and specificity for each test by using the formulas: LR+= sensitivity / (1 
– specificity) and LR- = specificity / (1 – sensitivity) [28]. 
3. Results 
3.1. Literature search 
The literature search resulted in a total of 721 unique articles. The 
screening of the articles by title and abstract led to an exclusion of 656 
articles. The remaining 65 articles were fully analyzed for eligibility 
using the inclusion and exclusion criteria. This resulted in an exclusion 
of 52 articles (Fig. 1). Therefore, 13 articles finally met the inclusion 
criteria and were included in this meta-analysis. Fig. 1 shows the 
detailed selection process. 
3.2. Study characteristics 
The characteristics of the included studies are shown in Table 1. 
Studies were published from 1998 to 2017 and the number of subjects 
varied between 78 and 4620. Thereafter, there were no new eligible 
studies published between 2017 and 2019. All the articles except one 
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were published in English. This article was written in Norwegian [29] 
and was translated into English to be able to extract the data. Diseases 
that were included in the studies as part of the ANCA-associated 
vasculitides (AAV) were granulomatosis with polyangiitis (GPA), 
microscopic polyangiitis (MPA), eosinophilic granulomatosis with pol-
yangiitis (eGPA), renal limited vasculitis (RLV), idiopathic rapidly pro-
gressive glomerulonephritis (iRPGN) and pauci-immune 
glomerulonephritis (PIGN). The diagnosis was made based on the clin-
ical features in all studies, according to the Chapel Hill Consensus [6]. 
ANCA testing was done with immunoassay and in some studies also with 
IIF. A total of 9 out of 13 studies included sensitivity and specificity of c- 
ANCA. 12 out of 13 studies reported sensitivity and specificity of anti- 
PR3. Only 4 out of 13 studies examined sensitivity and specificity of 
p-ANCA and 5 out of 13 studies anti-MPO. 
We used the QUADAS-2 tool to assess the quality of the articles. All 
studies had a potential risk of bias, when the QUADAS-2 tool was used. 
Appendix A shows a detailed assessment of each study. 
3.3. c-ANCA and anti-PR3 test value 
There were 9 studies that reported the sensitivity and specificity for 
c-ANCA IIF. These studies including their sensitivity and specificity with 
95% CI are shown in Fig. 2. The pooled sensitivity estimate of c-ANCA is 
75.2% (95% CI, 60.7% to 85.6%) and the pooled specificity estimate is 
98.4% (95% CI, 92.8% to 99.7%), as shown in the SROC curve (Fig. 3). 
A total of 12 studies described the sensitivity and specificity of anti- 
PR3 immunoassay. 10 studies used direct immunoassay as the method of 
immunoassay. An overview of these studies, as well as their sensitivity 
and specificity with 95% CI, is presented in Fig. 4. The pooled sensitivity 
estimate of anti-PR3 by direct immunoassay is 79.8% (95% CI, 59.0% to 
91.9%) and the pooled specificity estimate is 98.3% (95% CI, 93.9% to 
99.5%). This is also illustrated in the SROC curve (Fig. 5). Four studies 
used capture immunoassay with a pooled sensitivity of 84.9% (95% CI, 
71.0% to 92.8%) and a specificity of 98.8% (95% CI, 97.2% to 99.5%) 
for anti-PR3 [30,32,34,36]. The forest plot and SROC curve for anti-PR3 
using capture immunoassay is visible in Appendix B. Five studies used 
anchor immunoassay for determining anti-PR3 [22,30,32,33,36]. The 
pooled sensitivity for anchor immunoassay is 86.6% (95% CI, 74.8% to 
93.3%) and the pooled specificity is 96.8% (95% CI, 91.8% to 98.8%) 
(Appendix C). 
3.4. p-ANCA and anti-MPO test value 
A few studies investigated the p-ANCA and anti-MPO test value. 
There were 4 studies in total that studied sensitivity and specificity for p- 
ANCA tested by IIF. The pooled sensitivity for p-ANCA is 46.3% (95% CI, 
14.4% to 81.6%) and the pooled specificity is 91.4% (95% CI, 80.8% to 
96.4%). The forest plot and SROC curve are presented in respectively 
Figs. 6 and 7. 
The anti-MPO immunoassay was examined in 5 studies. The pooled 
sensitivity for anti-MPO is 58.1% (95% CI, 34.6% to 78.5%) and the 
specificity is 95.6% (95% CI, 92.0% to 97.6%) (Appendix D). All studies 
used direct immunoassay, except for Damoiseaux et al. [22] that used 
anchor immunoassay. For this reason, we did not perform separate an-
alyses for the different anti-MPO immunoassay methods. 
Noel et al. [35] used three types of direct ELISA testing. Therefore, 
we used the results of test A because this was the standard method. 
Radice et al. [36] used different tests for each assay, we chose to use the 
best performing test for direct ELISA, capture ELISA and anchor ELISA. 
Hagen et al. [13] described sensitivity and specificity for the different 
forms of AAV individually. We pooled the sensitivities and specificities 
to calculate a weighted average, using the formula for a weighted 
average as shown in Appendix E. Because of this, we could include the 
study in our meta-analysis. 
3.5. Subanalysis: eGPA 
The 2017 consensus on ANCA testing [23] is applicable for GPA and 
MPA only. We performed a subanalysis to assess if the sensitivity and 
specificity significantly differed if only studies including eGPA patients 
were included in the meta-analysis. 8 out of 13 studies 
[10,13,17,30,31,33,34,37] included eGPA patients. Repeating the meta- 
analysis, including those eight studies, sensitivity and specificity were 
comparable (data not shown). 
3.6. Likelihood ratios 
We have calculated the positive likelihood ratio (LR+) and negative 
likelihood ratio (LR-) of each diagnostic test using the pooled sensitiv-
ities and specificities. A likelihood ratio is used to estimate whether a 
test result changes the probability that an ANCA-associated vasculitis 
exists. For c-ANCA IIF, a LR+ of 47 and a LR- of 3.97 was calculated. 
Anti-PR3 by direct immunoassay gives a LR+ of 47 and a LR- of 4.87. For 
capture immunoassay anti-PR3 the LR+ is 71 and the LR- 6.54. A LR+ of 
27 was calculated for anchor immunoassay anti-PR3 alongside of a LR- 
of 7.22. For p-ANCA (LR+ 5.38 and LR- 1.70) and anti-MPO (LR+ 13 




Records screened by 
title and  
abstract (n= 721)
Records excluded: did not 




eligibility (n= 65) Full-text article excluded, 
with reasons (n= 52) 
Only about cost effectivity 
of the test (n= 1) 
No ANCA measurements 
(n= 1) 
Case-report (n= 2) 
Full article not available  
(n= 2) 
No sufficient data for a 2x2 
table (n= 7) 
Other diseases than AAV 
(n= 4) 
Letter/comment (n= 11) 
Review (n= 11) 
ANCA not performed as 
part of diagnosis (n= 13)  
Studies included in 
systematic review and 
meta-analysis (n= 13) 
Fig. 1. Flowchart of the study selection.  
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4. Discussion 
The only other available meta-analysis so far with a pooled sensi-
tivity and specificity for c-ANCA in a large group of patients is a review 
from Rao et al. from 1995, when measurement of anti-PR3 and anti-MPO 
was not yet clinical practice [38]. Sensitivity and specificity for c-ANCA 
in the previous study were comparable to the sensitivity and specificity 
in current meta-analysis. This meta-analysis shows the measurement of 
anti-PR3 and anti-MPO is of additional value, especially because of its 
high specificity. 
The recent 2017 international consensus [23] proposes that immu-
noassay can be used as a screening method for patients suspected of 
having ANCA-associated vasculitis, especially GPA and MPA, without 
ANCA screening with IIF first. This was based on the results of a 
multicenter European Vasculitis Study Group (EUVAS) evaluation 
[22,39]. The number of patients included in this evaluation was limited, 
however (GPA = 186, MPA = 65) [22]. This meta-analysis endorses the 
2017 consensus that PR3- and MPO-antibody immunoassay is the most 
reliable screening method for AAV. The consensus is currently only in 
use for GPA and MPA, although eGPA patients were included in 8/13 
studies. Repeating the analysis with the 8 studies including eGPA pa-
tients, sensitivity and specificity were comparable. However, this is 
probably explained by the fact that in most studies the eGPA patients 
were a minority of the included patients. Sensitivity and specificity of 
ANCA testing by IIF and immunoassay should be determined in a large 
cohort of eGPA patients only, to investigate this further. 
The pooled sensitivity for c-ANCA was 75.2% and for anti-PR3 was 
79.8% in case of direct immunoassay. For capture immunoassay the 
pooled sensitivity was 84.9% and for anchor immunoassay 86.6%. The 
95% confidence intervals for the sensitivity are wide. This raises the 
question if a positive ANCA test could be used as a suitable confirmation 
for the diagnosis of a suspected AAV. Ideally, a biopsy would prove the 
diagnosis of AAV [40]. However, in clinical practice, a biopsy is not 
always done and the diagnosis of AAV is based on both the clinical 
features and ANCA serology [41–43]. In this meta-analysis a combina-
tion of a positive c-ANCA and anti-PR3 was mostly associated with a 
diagnosis of granulomatosis with polyangiitis. Furthermore, a positive p- 
ANCA and anti-MPO was mainly related to microscopic polyangiitis. 
Alternative diagnoses that counted for a large amount of ANCA positive 
patients were inflammatory bowel disease, rheumatoid arthritis, an 
infection, such as human immunodeficiency virus, and connective tissue 
diseases. These patients were more often positive for c-ANCA or p-ANCA 
than for anti-PR3 or anti-MPO. Other reported diagnoses were drug- 
induced vasculitis, including cocaine-induced vasculitis [17,35] and 
are usually p-ANCA positive in combination with positive anti-MPO 
and/or positive anti-PR3. A positive anti-elastase test would also be 
present in most cases of drug-induced vasculitis [44]. When the ANCA 
IIF is negative, but the result of anti-MPO/PR3-testing is positive, there 
Table 1 
Study characteristics.  




Method of testing 
Damoiseaux et al. 
[22] 
2017 Ann Rheum Dis Comparative, multicenter, 
evaluation study 
924 GPA, MPA 251 IIF, immunoassay (anchor) 
De Joode et al. [30] 2014 Eur J Intern Med Retrospective, cohort study 198 GPA, MPA, RLV, eGPA 62 IIF, immunoassay (anchor 
and capture) 
Hagemo et al. [29] 2002 Tidsskr Nor 
Laegeforen 
Comparative study 292 GPA 27 IIF, immunoassay (direct) 
Hagen et al. [13] 1998 Kidney Int Multicenter, case-control 
study 
924 GPA, MPA, eGPA, 
iRPGN 
275 IIF, immunoassay (direct) 
Harris et al. [31] 1999 J Clin Pathol Prospective, clinical trial 344 GPA, MPA, polyarteritis 
nodosa, eGPA 
43 IIF, immunoassay (direct) 
Hellmich et al. [32] 2007 Clin Exp 
Rheumatol 
Prospective, clinical trial 530 GPA 86 IIF, immunoassay (direct, 
anchor and capture) 
Houben et al. [33] 2016 Medicine 
(Baltimore) 
Retrospective, cohort study 118 MPA, GPA, eGPA 119 Immunoassay (anchor) 
Ito-Ihara et al. [34] 2008 Clin Exp 
Rheumatol 
Comparative study 109 GPA, MPA, eGPA 64 Immunoassay (direct and 
capture) 
Noel et al. [35] 2013 Autoimmun Rev Evaluation study 59 GPA 19 Immunoassay (direct) 
Phatak et al. [10] 2017 Int J Rheum Dis Retrospective study 1563 GPA, MPA, eGPA, PIGN 27 IIF, immunoassay (direct) 
Radice et al. [36] 2013 Clin Chem Lab 
Med 
Comparative study 195 GPA 55 IIF, immunoassay (direct, 
anchor and capture) 
Schönermarck 
et al. [37] 
2001 Rheumatology 
(Oxford) 
Comparative study 4236 GPA, eGPA, MPA 384 IIF, immunoassay (direct) 
Stone et al. [17] 2000 Arthritis Care Res Cross-sectional study 787 GPA, eGPA, MPA, PIGN 69 IIF, immunoassay (direct) 
Abbreviations: GPA: Granulomatosis with Polyangiitis; MPA: Microscopic Polyangiitis; eGPA: Eosinophilic Granulomatosis with Polyangiitis; RLV: Renal Limited 
Vasculitis; iRPGN: Idiopathic Rapidly Progressive Glomerulonephritis; PIGN: Pauci-immune Glomerulonephritis; IIF: Indirect Immunofluorescence. 
Fig. 2. Forest plot: sensitivity and specificity for c-ANCA. TP (True Positives), FP (False Positives), FN (False Negatives) and TN (True Negatives) were calculated 
using the reported sensitivity, specificity, total subjects and positive tests. 
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may be a GPA present limited only to the upper respiratory tract. 
However, a study with IF-negative and anti-MPO or -PR3 positive results 
also revealed diagnoses of non-vasculitis conditions, mainly IBD and SLE 
[45]. 
Studies are not consistent in reporting the most common alternative 
diseases with dual positivity for PR3 and MPO antibodies. One study 
found that also a malignancy or a recurrent infection could be the cause 
of a dual positivity [46]. A clinician should also be aware of drug- 
induced vasculitis with dual positivity. ANCA-positivity is shown to be 
common with anti-thyroid medication, especially propylthiouracil 
[46,47]. The prevalence of AAV is rare, with a reported prevalence in the 
United States of 42/100,000 [11]. In a non-specialistic setting, the value 
of a positive ANCA test is low because of its low pre-test probability. 
However, in a specialistic setting, a positive ANCA test has a higher 
probability of being a true ANCA-associated vasculitis. 
We found high specificities for both c-ANCA (98.4%) and anti-PR3 
(direct immunoassay 98.3%, capture immunoassay 98.8% and anchor 
immunoassay 96.8%). This indicates that a negative ANCA test, espe-
cially in a clinical specialistic setting, could be of great value for 
excluding an AAV. A specificity of 100% is practically not possible in a 
diagnostic test, especially in biological markers such as ANCA as they 
slightly differ between patients. There are several known epitopes 
involved in the ANCAs and therefore the binding in an immunoassay 
could differ between patients [48]. 
Most commonly, ELISA was used as the test system of immunoassay. 
Direct, capture and anchor immunoassay showed a comparable sensi-
tivity and specificity (95% CI overlap) for detection of anti-PR3. All 
types of immunoassay showed a comparable specificity of almost 100%. 
Fig. 3. SROC curve for c-ANCA with pooled sensitivity (75.2%) and specificity (98.4%) with 95% CI.  
Fig. 4. Forest plot: sensitivity and specificity for anti-PR3 direct immunoassay. TP (True Positives), FP (False Positives), FN (False Negatives) and TN (True Neg-
atives) were calculated using the reported sensitivity, specificity, total subjects and positive tests. 
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We have also calculated the likelihood ratios for each test using the 
pooled sensitivity and specificity [49]. A LR+ of more than 10 is asso-
ciated with a clinical significant result [28]. In this study, the LR+ was 
above 10 for both anti-PR3 and anti-MPO. This means, when an ANCA- 
associated vasculitis is expected, a positive test result increases the 
chances of an ANCA-associated vasculitis even more. The other way 
around, the LR- was not below 1. This means a negative test result for 
anti-PR3 or anti-MPO, does not exclude an ANCA-associated vasculitis. 
This review has several limitations. The studies included had 
different purposes, characteristics, study designs, methods of testing, 
observed diseases and patient populations. Most studies were compar-
ative [13,22,29,34,36,37], some were prospective cohort studies 
[31,32,35] and some retrospective cohort studies [10,30,33]. The study 
by Stone et al. [17] was a cross-sectional study. Although different study 
designs were used in the included studies, we do not think that this 
substantially influenced the results. A diagnosis of AAV was namely 
confirmed according to the guidelines in all included studies. 
All studies included diseases that belong to the group of ANCA- 
associated vasculitides. GPA was the disease that was included in most 
studies. Therefore, the sensitivity and specificity of c-ANCA and anti- 
PR3 are mostly applicable on diagnosing GPA. 
We also performed a meta-analysis on the sensitivity of p-ANCA and 
anti-MPO. The pooled sensitivity was fairly low for both p-ANCA 
(46.3%) and anti-MPO (58.1%) and the confidence intervals were wide. 
This could be explained by the fact that the studies mostly included 
patients with GPA, and not with MPA. MPA is mostly associated with a 
positive p-ANCA and anti-MPO, as opposed to GPA. The specificity 
however, was high for both p-ANCA (91.4%) and anti-MPO (95.6%). 
A possible limitation is that two articles were not included, because 
the full article was not available. We contacted the authors; however, no 
reply was given. Additionally, it would also have been valuable to 
investigate studies that presented sensitivity and specificity when a 
combination of immunofluorescence and immunoassay was used. Most 
studies did not meet this criteria, however, although Stone et al. showed 
the combination of both IF and immunoassay increases both the positive 
and negative predictive value [17]. 
A quality assessment was performed. For systematic reviews on 
diagnostic test accuracy, the QUADAS-2 tool is advised [25]. This tool 
assesses each study on four domains, namely patient selection, index 
test, reference standard and flow/timing, using 14 predetermined 
Fig. 5. SROC curve for anti-PR3 direct immunoassay with pooled sensitivity (79.8%) and specificity (98.3%) with 95% CI.  
Fig. 6. Forest plot: sensitivity and specificity for p-ANCA. TP (True Positives), FP (False Positives), FN (False Negatives) and TN (True Negatives) were calculated 
using the reported sensitivity, specificity, total subjects and positive tests. 
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questions. All studies were scored to be at risk of bias. This was mostly 
due to uncertainty in the flow and timing domain. As concerned to flow, 
most studies did not explain withdrawals. As concerned to timing, time 
interval between reference standard and index test for diagnosis was not 
reported in most studies. In all studies the ANCA-testing and confirma-
tion of the vasculitis was done using the same guidelines, so the differ-
ences in time interval are not of great influence. Therefore, we have not 
excluded studies based on the quality assessment, because we think that 
the risk of bias would not significantly influence the results. 
There were a few studies that significantly stood out of the other 
studies with lower sensitivities and/or specificities in c-ANCA or anti- 
PR3. Hagen et al [13] had a low sensitivity compared to the other 
studies. This could be explained by a relatively large group of MPA 
patients, who have mostly a positive p-ANCA/anti-MPO instead of a 
positive c-ANCA/anti-PR3. Stone et al. [17] showed a relatively low 
sensitivity on both IIF and immunoassay. The authors explained this 
based on their study population. In their test population, a high preva-
lence of multiorgan system diseases was present that may easily mimic 
AAV. Combining IIF and immunoassay, however, did dramatically 
reduce their number of false-positive ANCA results. 
In summary, based on the findings of this meta-analysis, we support 
the 2017 international European consensus that primary screening by 
anti-PR3 and anti-MPO immunoassay, without the need for ANCA 
testing by IIF, should be included in the workup towards a diagnosis of 
an ANCA-associated vasculitis [23]. Direct, capture and anchor immu-
noassay showed a comparable sensitivity and specificity. An anti-PR3 
positive result would especially be of great value when GPA is sus-
pected and an anti-MPO could be used for diagnosing MPA. In routine 
clinical practice, ANCA testing is not of great value as the prevalence of 
AAV is low and positive ANCAs also occur in more common diseases, 
like inflammatory bowel disease or rheumatoid arthritis. Therefore, 
suspicion of an AAV based on the clinical features is crucial for a correct 
interpretation of the ANCA serology. Requesting ANCA testing based on 
clinical features could also lead to a significant decrease of costs, as 
described by a recent French cost-efficiency evaluation study [50]. A 
biopsy remains the most reliable way to diagnose AAV. However, as that 
is not always possible and considering that a biopsy is invasive for the 
patient, ANCA serology takes an important place in the workup to the 
diagnosis of ANCA-associated vasculitis. 
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Fig. 7. SROC curve for p-ANCA with pooled sensitivity (46.3%) and specificity (91.4%) with 95% CI.  
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Fig. A.1. QUADAS-2 quality assessment.  
Appendix B 
Forest plot and SROC curve for anti-PR3 capture immunoassay.
Fig. B.1. Forest plot: sensitivity and specificity for anti-PR3 capture immunoassay. TP (True Positives), FP (False Positives), FN (False Negatives) and TN (True 
Negatives) were calculated using the reported sensitivity, specificity, total subjects and positive tests.  
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Fig. B.2. SROC curve for anti-PR3 capture immunoassay with pooled sensitivity (84.9%) and specificity (98.8%) with 95% CI.  
Appendix C 
Forest plot and SROC curve for anti-PR3 anchor immunoassay.
Fig. C.1. Forest plot: sensitivity and specificity for anti-PR3 anchor immunoassay. TP (True Positives), FP (False Positives), FN (False Negatives) and TN (True 
Negatives) were calculated using the reported sensitivity, specificity, total subjects and positive tests.  
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Fig. C.2. SROC curve for anti-PR3 anchor immunoassay with pooled sensitivity (86.6%) and specificity (96.8%) with 95% CI.  
Appendix D 
Forest plot and SROC curve for anti-MPO immunoassay.
Fig. D.1. Forest plot: sensitivity and specificity for anti-MPO immunoassay. TP (True Positives), FP (False Positives), FN (False Negatives) and TN (True Negatives) 
were calculated using the reported sensitivity, specificity, total subjects and positive tests.  
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Fig. D.2. SROC curve for anti-MPO immunoassay with pooled sensitivity (58.1%) and specificity (95.6%) with 95% CI.  
Appendix E 









With i = {Granulomatosis with polyangiitis, Microscopic polyangiitis, Idiopathic RPGN, Classic polyarteritis nodosa, Eosinophilic granulomatosis 
with polyangiitis} and with wi = numbers of patiënts with disease i and xi = sensitivity of disease i. 
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